On March 2, 2026, Novo Nordisk announced a 432 million Euro investment (approximately 3.2 billion DKK) in its Monksland facility located in Athlone, Ireland. This funding is dedicated to upgrading and retrofitting the existing tabletting plant, specifically designed to boost production capacity for current and upcoming oral GLP-1 treatments.
This expansion marks a major strategic milestone, positioning the Irish site as a vital hub for supplying markets outside the United States. By enhancing its oral product manufacturing capabilities, the company aims to meet the surging global demand for chronic disease therapies. This move further solidifies Ireland’s reputation as a premier pharmaceutical destination, currently hosting 9 of the world’s top 10 pharma leaders.
The project is estimated to generate up to 600 construction jobs and will be supported by the expertise of the facility’s existing 260-strong workforce. Construction activities have already commenced, with a phased completion scheduled between late 2027 and 2028. The initiative reflects a commitment to high-quality, environmentally sustainable production to serve millions of patients living with serious chronic conditions worldwide.